We are not an emergency medical providerFor emergencies, contact local emergency services immediately
English简体中文العربية
Request Intake
China-developed oncology innovation

Innovative Medicines Developed in China

Explore selected oncology medicines developed by Chinese biopharmaceutical companies. International access begins with diagnosis review, indication matching and a specialist-led treatment plan—not a product request.

Request a Medication Pathway Review
Four selected therapiesTwo bispecific antibodies and two PD-1 monoclonal antibodiesInformation reviewed 25 August 2026
Why this matters

A growing portfolio of locally developed cancer medicines

China’s oncology ecosystem now includes domestically developed checkpoint inhibitors and bispecific antibodies with NMPA-approved indications. For an international patient, the practical question is whether a medicine is appropriate, available and legally accessible within a hospital-led care pathway.

Indication-specific reviewHospital and pharmacy confirmationWritten treatment and cost estimate
Selected medicines

Products in the supplied material

Product images are used for identification. Approved indications and presentations can change; the treating hospital must verify the latest prescribing information.

Toripalimab injection TUOYI product packaging and vial
01
TUOYI®

Toripalimab Injection

特瑞普利单抗注射液

Type
PD-1 monoclonal antibody
Developer
Junshi Biosciences
Clinical focus
China-approved indications include selected melanoma, urothelial carcinoma and nasopharyngeal carcinoma settings; the exact current label must be checked for each patient.

Presentation: 240 mg (6 mL) and 80 mg (2 mL) presentations shown in supplied product material

Cadonilimab injection product packaging and vial
02
Kaitanni®

Cadonilimab Injection

卡度尼利单抗注射液

Type
PD-1 / CTLA-4 bispecific antibody
Developer
Akeso
Clinical focus
China-approved uses include defined cervical cancer and gastric or gastroesophageal junction cancer settings, subject to the current NMPA label.

Presentation: 125 mg (10 mL) / vial

Ivonescimab and cadonilimab injection packaging in a clinical setting
03
Ivonescimab

Ivonescimab Injection

依沃西单抗注射液

Type
PD-1 / VEGF bispecific antibody
Developer
Akeso
Clinical focus
Approved in China for defined non-small cell lung cancer settings, including indication-specific molecular and treatment-history requirements.

Presentation: 100 mg (10 mL) / vial shown in supplied product material

Sintilimab injection TYVYT product packaging and vial
04
TYVYT®

Sintilimab Injection

信迪利单抗注射液

Type
PD-1 monoclonal antibody
Developer
Innovent Biologics / Eli Lilly
Clinical focus
China-approved indications span selected lymphoma, lung, liver, esophageal, gastric and other cancer settings; use depends on the exact current label and individual assessment.

Presentation: 100 mg (10 mL) / vial

International access pathway

Start with the patient, not the product

Our coordination team helps organize records and identify an appropriate specialist. The hospital decides whether a medicine is clinically indicated and available.

  1. 01Submit the diagnosis and current treatment history
  2. 02Confirm biomarkers, prior therapies and indication fit
  3. 03Coordinate hospital review and a written estimate
  4. 04Plan treatment only after physician acceptance

Important medical and regulatory notice. China Medical Net does not prescribe, dispense, sell or export medicines. This page is educational and does not recommend a drug for any individual. Oncology medicines may cause serious adverse reactions and must be prescribed and administered by qualified professionals. Approval status, indications, reimbursement and availability differ by jurisdiction and may change.

Primary referencesAkeso regulatory milestonesInnovent: approved sintilimab indicationsFDA: toripalimab approval information